RA
TVRD

Rosalind Advisors’s Tvardi Therapeutics TVRD Stock Holding History

Rosalind Advisors’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-43,025
Closed -$1.41M – 41
2024
Q1 		$1.41M Buy
+43,025
New +$1.12M 1.32% 24

Other funds holding TVRD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Rosalind Advisors's TVRD Position: Q2 2024 in Review

Rosalind Advisors sold out of Tvardi Therapeutics (TVRD) in Q2 2024, closing a stake of 43,025 shares — an estimated $1.41M sold.

Rosalind Advisors first reported a position in TVRD in Q1 2024 and held it in 1 quarter. The position peaked at $1.41M in Q1 2024. 79 funds tracked by Wall St. Rank hold TVRD as of Q2 2024.

  • Rosalind Advisors reported no remaining Tvardi Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Rosalind Advisors sold 43,025 Tvardi Therapeutics shares in Q2 2024, an estimated $1.41M.
  • Rosalind Advisors first reported a position in Tvardi Therapeutics in Q1 2024 and held it in 1 quarter.
  • Rosalind Advisors's Tvardi Therapeutics position peaked at $1.41M in Q1 2024.
  • 79 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2024.

Based on Rosalind Advisors's 13F filing for Q2 2024, filed 12 Jul 2024.